Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Justin J. File resigned as Secretary at Evofem Biosciences, Inc..
- Action
- resigned
- Role
- Secretary
Exact text from the filing
which was left vacant as a result of the resignation by Justin J. File.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Saundra Pelletier was appointed as Secretary at Evofem Biosciences, Inc..
- Action
- appointed
- Role
- Secretary
Exact text from the filing
On April 5, 2023, the Company’s board of directors appointed Saundra Pelletier to fill the role as the Secretary of the Company, which was left vacant as a result of the resignation by Justin J. File.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Evofem Biosciences, Inc. entered into Securities Purchase Agreement with Investors valued at Senior subordinate convertible notes due in aggregate original principal amount of $769,230.76, inte (effective 2023-04-05).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- Investors
- Value
- Senior subordinate convertible notes due in aggregate original principal amount of $769,230.76, inte
- Effective
- 2023-04-05
Exact text from the filing
On April 5, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (“ SPA ”), with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $769,230.76 (the “ Notes ”) and warrants (“ Warrants ”) to purchase an aggregate 26,923,077 shares of common stock, par value $0.0001 per share (the “ Common Stock ”) (collectively, the “ Offering ”).
View on SEC.gov